Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefi...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2017-08, Vol.9 (8), p.533-550
Main Authors: In, Gino K., Hu, James S., Tseng, William W.
Format: Article
Language:English
Subjects:
Alkylating agents
Anthracycline
Cytotoxic agents
Cytotoxicity
Immunotherapy
Malignancy
Metastases
Metastasis
Monoclonal antibodies
Rare diseases
Reviews
Soft tissue sarcoma
Survival
Targeted cancer therapy
Taxanes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefit beyond the first-line setting; across all high-grade STS subtypes, median overall survival remains approximately 12–18 months for advanced metastatic disease. The development of targeted therapies has led to recent US Food and Drug Administration approval of four new treatments for high-grade STS in the advanced metastatic setting. Among these, olaratumab is most notable for its improvement in overall survival for patients with anthracycline-naïve disease. Further progress in STS management will rely on novel trial design, subtype-specific therapies and validation of biomarkers to tailor therapy. Immunotherapy has shown promise as a new, but yet undiscovered frontier in the management of STS.
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/1758834017712963